Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ASKB589 Injection NCT04632108 |
P1/2 | Active, not recruiting | Malignant Solid Tumor | 199 | 2025-10-31 (+38 mo) |
| ASKC200 NCT07742852 |
P2 | Active, not recruiting | Osteoarthritis (OA) of the Knee; Pain | 175 | 2026-04-28 |
| ASK0912 for Injection NCT07759934 |
P2 | Recruiting | Ventilator-associated Bacterial Pneumonia (VABP); Hospital-acquired Bacterial Pneumonia (HABP) | 60 | 2027-10-20 |
| ASKC202+ Limertinib NCT07109531 |
P3 | Recruiting | Locally Advanced or Metastatic NSCLC | 286 | 2027-10-31 |
| ASKC202 NCT07897188 |
P3 | Not yet recruiting | EGFR Activating Mutation; Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | 425 | 2030-12-30 |